Published in Medicine and Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at BioSante Pharmaceuticals, Inc.
Report 1: BioSante Pharmaceuticals, Inc. (AMEX: BPA) announced that it and a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), have signed an amendment to their development and license agreement under which Teva and BioSante will reinitiate their collaboration on the development of a male testosterone therapy product for the U.S. market. Effective immediately, Teva has withdrawn its previous notice of its desire to terminate the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.